Angiotech partner announces completion of enrollment in pivotal clinical trial for next-generation paclitaxel-eluting coronary s
22 Februar 2005 - 2:35PM
PR Newswire (US)
Angiotech partner announces completion of enrollment in pivotal
clinical trial for next-generation paclitaxel-eluting coronary
stent system ATLAS study evaluating safety and efficacy of TAXUS(R)
Liberte(TM) VANCOUVER, Feb. 22 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP) corporate
partner, Boston Scientific ("BSC"), announced today that it has
completed enrollment in its ATLAS clinical trial. ATLAS is the
first trial using Boston Scientific's new Liberte(TM) coronary
stent as a platform for its paclitaxel-eluting coronary stent
system. TAXUS(R) Liberte(TM) is the next generation to Boston
Scientific's first paclitaxel- eluting coronary stent system,
TAXUS(TM) Express(2)(TM), which is the worldwide leader in the
coronary stent market today. The ATLAS trial is a global,
multicenter pivotal study designed to support U.S. Food and Drug
Administration approval of the TAXUS Liberte stent system. It is
assessing the safety and efficacy of a slow-release dose
formulation paclitaxel-eluting TAXUS Liberte stent system for the
treatment of coronary artery disease. ATLAS has enrolled 872
patients at 72 sites in the United States, Canada, Australia, New
Zealand, Singapore and Hong Kong. The primary endpoint for the
study is target vessel revascularization at nine months. Enrollment
began in August 2004. In addition to the ATLAS trial, the TAXUS
Liberte program includes several expansion studies for long lesion
stenting, small vessel stenting and direct stenting of coronary
lesions. The expansion studies are expected to begin enrollment in
the next several weeks, as stated by BSC. BSC received the CE Mark
for the bare metal Liberte stent system in December 2003 and plans
to launch the TAXUS Liberte system in Europe later this year. The
TAXUS Liberte system was launched in 18 other international markets
in January. "I am very pleased that enrollment has concluded in
this pivotal study so quickly," said John Ormiston, M.D.,
Interventional Cardiologist, Mercy Hospital and Green Lane
Cardiovascular Unit, Auckland, New Zealand, and Co-Principal
Investigator of the ATLAS study. "We are excited about the
potential for the new Liberte stent design to provide clinicians
easier access to vessels indicated for drug-eluting stent
treatment." The Liberte stent features the Veriflex(TM) stent
design, a highly flexible cell geometry with thin struts and
uniform cell distribution. BSC states that this new platform offers
improved deliverability and conformability in challenging anatomy.
It also features the enhanced TrakTip(TM) catheter tip, mounted on
the Maverick(2)(TM) delivery catheter, which provides better lesion
crossability. In addition, TrakTip has a low lesion-entry profile,
which further improves crossability, BSC reports. BSC acquired
worldwide exclusive rights from Angiotech to use paclitaxel to coat
its coronary stent products and has co-exclusive rights to other
vascular and non-vascular products. Vancouver-based Angiotech
Pharmaceuticals, Inc., a specialty pharmaceutical company focusing
on drug-coated medical devices and biomaterials, is dedicated to
enhancing the performance of medical devices and biomaterials
through the innovative uses of pharmacotherapeutics. To find out
more about Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. Statements contained herein that are not
based on historical or current fact, including without limitation
statements containing the words "anticipates", "believes", "may",
"continue", "estimate", "expects", "may" and "will" and words of
similar import, constitute "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, among others, the
following: general economic and business conditions, both
nationally and in the regions in which the Company operates;
technology changes; competition; changes in business strategy or
development plans; the ability to attract and retain qualified
personnel; existing governmental regulations and changes in, or the
failure to comply with, governmental regulations; liability and
other claims asserted against the Company; and other factors
referenced in the Company's filings with the United States
Securities and Exchange Commission or the Canadian securities
regulators. Given these uncertainties, readers are cautioned not to
place undue reliance on such forward-looking statements. The
Company does not assume the obligation to update any
forward-looking statements. CONTACTS: Todd Young, Angiotech
Pharmaceuticals (Analysts & Investors), (604) 221-7676 ext 6933
Rui Avelar, Angiotech Pharmaceuticals, Inc. (Analysts), (604)
221-7676 ext 6996 Eric Starkman, Starkman & Associates (Media),
(212) 252-8545 ext 12 DATASOURCE: Angiotech Pharmaceuticals, Inc.
CONTACT: Todd Young, Angiotech Pharmaceuticals (Analysts &
Investors), (604) 221-7676 ext 6933; Rui Avelar, Angiotech
Pharmaceuticals, Inc. (Analysts), (604) 221-7676 ext 6996; Eric
Starkman, Starkman & Associates (Media), (212) 252-8545 ext 12
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024